Status
Conditions
Treatments
About
This study evaluates the diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) with rest perfusion imaging for the diagnosis of myocarditis. Patients with clinical suspicion of myocarditis will be recruited and undergo a rest myocardial perfusion scan and a FDG PET/CT scan following a myocardial suppression protocol.
Full description
Myocarditis is characterized by myocardial inflammation, which can lead to fibrosis and heart failure.
FDG PET/CT, with appropriate suppression protocol including high-fat-low-carbohydrate diet, fasting, and IV heparin, can be use to detect myocardial inflammation. It is frequently used for the diagnosis of inflammation in cardiac sarcoidosis. After the initial inflammatory phase, inflammation resolves and fibrosis can seen. Resting perfusion imaging will allow identification of fibrosis. The combination of FDG PET/CT and rest perfusion imaging could allow detection of the various phases of myocarditis; inflammation and fibrosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
18 years of age or older
Clinical suspicion of myocarditis due to findings such as:
Women of childbearing potential must have a negative urine or blood pregnancy test
Capable of giving informed consent and the consent must be obtained prior to any study related procedures
Subject's with body mass index inferior or equal to 45 kg/m2
Exclusion criteria
Loading...
Central trial contact
Francois Harel, MD PhD; Matthieu Pelletier-Galarneau, MD MSc FRCPC
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal